Takeda Pharmaceutical Company Limited

Thank you very much for taking time out of the very busy schedule to join us for this first quarter earnings call by Takeda or FY24.

I'm the master of the ceremony today.

My name is Sir O'Reilly from IR. I'm the head of IR. I would like to explain the language setting first. Please find the language button at the bottom of the Zoom window. If you wish to listen in Japanese, please select Japanese. If English, please select English. If you want to listen to the original, please turn them off. Before starting, I would like to remind everyone that we'll be discussing forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in the most recent Form 20F and in our other SEC findings. Please also refer to the important notice on page 2 of the presentation regarding forward-looking statements and non-IFRS financial measures, which will also be discussed during this call. Definitions of our non-IRFS measures and reconciliations with comparable IFRS financial measures are included in the appendix of the presentation. Now, without further ado, we would like to move on to the presentation of the day, which will be given by Christoph Weber, President-CEO, Milano Furuta, Chief Financial Officer, and Andy Plump, R&D President. Following the presentations, we have time for Q&A. Now, let us begin.